Published in Pharmacol Ther on October 04, 2009
The functional -765G→C polymorphism of the COX-2 gene may reduce the risk of developing crohn's disease. PLoS One (2010) 0.80
Role of cyclooxygenase isoforms in the altered excitatory motor pathways of human colon with diverticular disease. Br J Pharmacol (2014) 0.78
Effect of ω-3 fatty acid on gastrointestinal motility after abdominal operation in rats. Mediators Inflamm (2011) 0.75
Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology (2004) 4.05
Endothelial dysfunction in small arteries of essential hypertensive patients: role of cyclooxygenase-2 in oxidative stress generation. Hypertension (2013) 2.82
Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms. Am J Gastroenterol (2009) 2.57
Molecular basis of resistance to azole antifungals. Trends Mol Med (2002) 2.48
Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res (2006) 2.38
Chronic intestinal pseudo-obstruction. World J Gastroenterol (2008) 2.29
A 5-year experience of benign pancreatic hyperenzymemia. Pancreas (2014) 2.27
The London Classification of gastrointestinal neuromuscular pathology: report on behalf of the Gastro 2009 International Working Group. Gut (2010) 1.89
Lack of pharmacokinetic bioequivalence between generic and branded amoxicillin formulations. A post-marketing clinical study on healthy volunteers. Br J Clin Pharmacol (2009) 1.81
Deamidated gliadin peptide antibodies as a routine test for celiac disease: a prospective analysis. J Clin Gastroenterol (2010) 1.70
Immunity, inflammation and cancer: a leading role for adenosine. Nat Rev Cancer (2013) 1.69
Hydrogen sulfide is a novel prosecretory neuromodulator in the Guinea-pig and human colon. Gastroenterology (2006) 1.66
Enteric neuroplasticity evoked by inflammation. Auton Neurosci (2006) 1.55
Immune-mediated neural dysfunction in a murine model of chronic Helicobacter pylori infection. Gastroenterology (2002) 1.50
Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome. Gastroenterology (2009) 1.50
Gastrointestinal neuromuscular pathology: guidelines for histological techniques and reporting on behalf of the Gastro 2009 International Working Group. Acta Neuropathol (2009) 1.48
Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res (2008) 1.46
Adverse reactions to oncologic drugs: spontaneous reporting and signal detection. Expert Rev Clin Pharmacol (2014) 1.45
Natural history of chronic idiopathic intestinal pseudo-obstruction in adults: a single center study. Clin Gastroenterol Hepatol (2005) 1.42
Guillain-Barré syndrome following adalimumab treatment. Clin Exp Rheumatol (2012) 1.41
Intestinal serotonin release, sensory neuron activation, and abdominal pain in irritable bowel syndrome. Am J Gastroenterol (2011) 1.41
Cholinergic toxic syndrome by the anticancer drug irinotecan: acetylcholinesterase does not play a major role. Clin Pharmacol Ther (2002) 1.39
New understanding of gluten sensitivity. Nat Rev Gastroenterol Hepatol (2012) 1.39
Interactions between commensal bacteria and gut sensorimotor function in health and disease. Am J Gastroenterol (2005) 1.35
CB(1) signaling in forebrain and sympathetic neurons is a key determinant of endocannabinoid actions on energy balance. Cell Metab (2010) 1.33
Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol Pharmacol (2005) 1.31
Periorbital necrotising fasciitis. Br J Ophthalmol (2009) 1.28
Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer. J Clin Oncol (2002) 1.27
Inclusion of rituximab in treatment protocols for non-Hodgkin's lymphomas and risk for progressive multifocal leukoencephalopathy. Oncologist (2010) 1.26
Biosimilar drugs : concerns and opportunities. BioDrugs (2007) 1.26
A global perspective on irritable bowel syndrome: a consensus statement of the World Gastroenterology Organisation Summit Task Force on irritable bowel syndrome. J Clin Gastroenterol (2012) 1.21
A mutation in telethonin alters Nav1.5 function. J Biol Chem (2008) 1.20
Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer. Mol Cancer Ther (2006) 1.20
Regulation of enteric functions by adenosine: pathophysiological and pharmacological implications. Pharmacol Ther (2008) 1.19
Pharmacological issues of linezolid: an updated critical review. Clin Pharmacokinet (2010) 1.16
The immune system in irritable bowel syndrome. J Neurogastroenterol Motil (2011) 1.16
Vascular generation of tumor necrosis factor-α reduces nitric oxide availability in small arteries from visceral fat of obese patients. J Am Coll Cardiol (2011) 1.16
Safety concerns associated with the use of serotonin reuptake inhibitors and other serotonergic/noradrenergic antidepressants during pregnancy: a review. Clin Ther (2009) 1.15
Teaching pharmacovigilance: the WHO-ISoP core elements of a comprehensive modular curriculum. Drug Saf (2014) 1.14
Vascular endothelial growth factor levels in immunodepleted plasma of cancer patients as a possible pharmacodynamic marker for bevacizumab activity. J Clin Oncol (2007) 1.12
Dyspeptic symptoms and gastric emptying in the irritable bowel syndrome. Am J Gastroenterol (2002) 1.12
Hydrogen sulphide: novel opportunity for drug discovery. Med Res Rev (2010) 1.11
Gastrointestinal dysmotility in mitochondrial neurogastrointestinal encephalomyopathy is caused by mitochondrial DNA depletion. Am J Pathol (2008) 1.11
Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines. Clin Cancer Res (2004) 1.11
Contrast harmonic endoscopic ultrasonography in the characterization of pancreatic metastases (with video). Pancreas (2014) 1.09
Pharmacogenetics of anticancer drug sensitivity in non-small cell lung cancer. Pharmacol Rev (2003) 1.08
Non-celiac gluten sensitivity: questions still to be answered despite increasing awareness. Cell Mol Immunol (2013) 1.08
Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer. Clin Cancer Res (2009) 1.06
Overlap of functional heartburn and gastroesophageal reflux disease with irritable bowel syndrome. World J Gastroenterol (2013) 1.05
Platelet serotonin transporter in patients with diarrhea-predominant irritable bowel syndrome both before and after treatment with alosetron. Am J Gastroenterol (2003) 1.04
Immunohistochemical analysis of myenteric ganglia and interstitial cells of Cajal in ulcerative colitis. J Cell Mol Med (2012) 1.04
Chronic intestinal pseudo-obstruction. Best Pract Res Clin Gastroenterol (2007) 1.03
Identifying adverse drug reactions associated with drug-drug interactions: data mining of a spontaneous reporting database in Italy. Drug Saf (2010) 1.02
Cyclooxygenase-1 is involved in endothelial dysfunction of mesenteric small arteries from angiotensin II-infused mice. Hypertension (2006) 1.02
Inhibition of adenosine deaminase attenuates inflammation in experimental colitis. J Pharmacol Exp Ther (2007) 1.01
Adenosine deaminase in the modulation of immune system and its potential as a novel target for treatment of inflammatory disorders. Curr Drug Targets (2012) 1.01
Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer. Cancer Chemother Pharmacol (2009) 1.01
Pharmacokinetics of azithromycin in lung tissue, bronchial washing, and plasma in patients given multiple oral doses of 500 and 1000 mg daily. Pharmacol Res (2002) 1.01
A rapid high-performance liquid chromatography method to measure linezolid and daptomycin concentrations in human plasma. Ther Drug Monit (2010) 1.01
Altered prejunctional modulation of intestinal cholinergic and noradrenergic pathways by alpha2-adrenoceptors in the presence of experimental colitis. Br J Pharmacol (2003) 1.01
Effect of gluten free diet on immune response to gliadin in patients with non-celiac gluten sensitivity. BMC Gastroenterol (2014) 1.00
Mechanisms underlying visceral hypersensitivity in irritable bowel syndrome. Curr Gastroenterol Rep (2011) 0.99
Role of coxibs in the strategies for gastrointestinal protection in patients requiring chronic non-steroidal anti-inflammatory therapy. Pharmacol Res (2008) 0.99
Mucosal permeability and immune activation as potential therapeutic targets of probiotics in irritable bowel syndrome. J Clin Gastroenterol (2012) 0.99
Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs. Clin Pharmacokinet (2002) 0.99